Efficacy and safety of dose-escalated alectinib in patients with metastatic ALK-positive NSCLC and CNS relapse on standard dose alectinib

被引：0
|
作者：
Cheung, Justin Matthew
Kang, Jiyoon
Yeap, Beow Y.
Peterson, Jenn
Do, Andrew
Digumarthy, Subba R.
Gainor, Justin F.
Lin, Jessica Jiyeong
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21079
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis
    Samaca-Samaca, Daniel
    Prieto-Pinto, Laura
    Perez, Andres Yepes
    Valderrama, Carolina
    Hernandez, Fabian
    LUNG CANCER MANAGEMENT, 2023, 12 (02)
  • [12] Alectinib in crizotinib-resistant, ALK-positive NSCLC
    Jassem, Jacek
    LANCET ONCOLOGY, 2016, 17 (02): : 134 - 135
  • [13] Alectinib surpasses crizotinib for untreated ALK-positive NSCLC
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2017, 18 (07): : E377 - E377
  • [14] Efficacy and survival outcomes of alectinib vs. crizotinib in ALK-positive NSCLC patients with CNS metastases: A retrospective study
    Liu, Qing
    Fu, Ying
    Guo, Jun
    Fu, Chunqiu
    Tang, Ning
    Zhang, Chufeng
    Han, Xiao
    Wang, Zhehai
    ONCOLOGY LETTERS, 2024, 27 (05)
  • [15] Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC
    Zhang, Chao
    Yan, Li-Xu
    Jiang, Ben-Yuan
    Wu, Yi-Long
    Zhong, Wen-Zhao
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (06) : E95 - E99
  • [16] Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients
    Yoshida, T.
    Oya, Y.
    Tanaka, K.
    Junichi, S.
    Yoshitsugu, H.
    Hida, T.
    Yatabe, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S619 - S619
  • [17] Patterns and Clinical Impact of Alectinib Dose Reduction in Patients with ALK-Positive Non- Small Cell Lung Cancer (NSCLC)
    To, B.
    Farid, S.
    Zhao, S.
    Li, M.
    Amirmokhtari, N.
    Wei, L.
    Memmott, R.
    Alahmadi, A.
    He, K.
    Kaufman, J.
    Roof, L.
    Shields, P.
    Carbone, D.
    Otterson, G.
    Presley, C.
    Owen, D.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S644 - S645
  • [18] Response to "Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence"
    Groenland, Stefanie L.
    Geel, Dieuwertje R.
    Beijnen, Jos H.
    Smit, Egbert F.
    Huitema, Alwin D. R.
    Steeghs, Neeltje
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (05) : 1164 - 1164
  • [19] Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
    Ulhoi, Maiken Parm
    Sorensen, Boe Sandahl
    Meldgaard, Peter
    CASE REPORTS IN ONCOLOGY, 2021, 14 (03): : 1323 - 1327
  • [20] Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients.
    Yoshida, Tatsuya
    Oya, Yuko
    Shimizu, Junichi
    Tanaka, Kosuke
    Horio, Yoshitsugu
    Hida, Toyoaki
    Yatabe, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345